IRAK4 Inhibitor Crystal Forms for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for IRAK4-related diseases lack effective therapeutic agents that can modulate the activity of Interleukin-1 receptor associated kinase 4 (IRAK4), a key node in the innate immune response, to address chronic lung disease and inflammatory bowel disease.
Innovation Solution
Development of crystalline forms of IRAK4 inhibitors, such as hydrochloride, sulfate, methanesulfonate, maleate, and p-methylbenzenesulfonate salts, which exhibit specific diffraction peaks in X-ray powder diffraction patterns, enhancing solubility, pharmacokinetic properties, and stability for potential therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If crystalline forms of IRAK4 inhibitors are developed with specific diffraction peaks, then solubility and pharmacokinetic properties are improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies parameter changes by developing specific crystalline forms of IRAK4 inhibitors with controlled physical and chemical parameters. By controlling the crystallization process to achieve specific diffraction patterns (e.g., peaks at 2θ: 6.25±0.20°, 16.15±0.20°, 21.79±0.20°), the solubility and pharmacokinetic properties are optimized. This involves adjusting temperature, pressure, and chemical environment during crystallization to obtain the desired crystal structure.
Solution Approach 2:
The patent utilizes phase transitions in the crystallization process to transform the inhibitor from amorphous or liquid state to crystalline state with specific properties. By controlling the phase transition during crystallization, the patent achieves crystalline forms with specific diffraction peaks that exhibit improved solubility and pharmacokinetic characteristics while maintaining manufacturing feasibility.
2Reliability
If crystalline forms with specific diffraction peaks are produced, then pharmacokinetic properties and stability are enhanced, but preparation process complexity increases
Solution Approach 1:
The patent employs parameter changes by optimizing crystallization conditions including temperature profiles, pH levels, and solvent composition to achieve stable crystalline forms with specific diffraction patterns. By controlling these parameters, the patent enhances stability while maintaining a manageable preparation process.
Solution Approach 2:
The patent applies self-service principles by utilizing the inherent properties of the IRAK4 inhibitor molecules to form stable crystalline structures. The molecules self-organize into crystalline lattices with specific diffraction patterns when subjected to appropriate crystallization conditions, reducing the need for complex external intervention and simplifying the preparation process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms of IRAK4 inhibitors demonstrate improved solubility, pharmacokinetic properties, and stability, providing a potential therapeutic advantage for treating IRAK4-related diseases.
Implementation Method 1
a crystalline form of the hydrochloride of the compound of formula (I), a crystalline form of the sulfate of the compound of formula (I), a crystalline form of the methanesulfonate of the compound of formula (I), a crystalline form of the maleate of the compound of formula (I), or a crystalline form of the p-methylbenzenesulfonate of the compound of formula (I)
Implementation Method 2
the crystalline form of a compound of formula (I), a salt thereof, and a method for preparing the crystalline form
Data Source
AI summary
Provided are a crystal of a compound of formula (I), salt thereof, a crystal of the salt thereof, and a preparation method for the crystal. Also comprised are applications of the compound and the crystal in preparation of drugs for treating IRAK4-related diseases.